• Loading stock data…

Shattuck Labs Announces Participation in Upcoming September Conferences

Last Updated on September 1, 2022 by GlobeNewsWire

AUSTIN, TX & DURHAM, NC, Sept. 01, 2022 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in two investor conferences in September 2022.

Presentation Details

Conference: Citi’s 17th Annual BioPharma ConferenceFormat: Targeted Oncology panel discussion with covering analyst Yigal NochomovitzPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: September 8, 2022Time: 2:40 p.m. ET

Conference: H.C. Wainwright 24th Annual Global Investment ConferenceFormat: Corporate PresentationPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: September 12, 2022Time: 7:00 a.m. ET

A live webcast of the presentations will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.

About Shattuck Labs, Inc.Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC(R), platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s SL-172154 (SIRP?-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN(TM), platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact: Conor RichardsonSenior Director, Finance & Investor RelationsShattuck Labs, Inc.InvestorRelations@shattucklabs.com




Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: